Desmopressin

Generic Name: Desmopressin

Brand Names: Ddavp, Nocdurna, Octostim

Drug Type: Small Molecule

Chemical Formula: C_₄₆H_₆₄N_₁₄O_₁₂S_₂

CAS Number: 16679-58-6

Unique Ingredient Identifier: ENR1LLB0FP

Background: Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasm...

Indication: 1.治疗中枢性尿崩症，可减少尿量、提高尿渗透压、降低血浆渗透压；

2.用于尿崩症的诊断和鉴别诊断；

3.用于治疗夜间遗尿症（六岁或以上的患者）；

4.部分类型（甲型血友病和Ⅰ型血管性假血友病）的血友病及其他出血性疾病。

Associated Conditions: Bleeding, Hypothalamic Injury-induced Obesity (HIO), Nocturia, Nocturnal Polyuria, Polydipsia, Polyuria, Primary Nocturnal Enuresis

Associated Therapies: -

Clinical Trials

Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery

Phase 4

Completed

Conditions: Patients Undergoing Endoscopic Sinus Surgery

Interventions: Drug: Desmopressin
Drug: saline

First Posted Date: 2014-04-29

Last Posted Date: 2017-06-06

Lead Sponsor: Tao Zhang

Target Recruit Count: 60

Registration Number: NCT02125188

Locations: 🇨🇳
First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery

Phase 4

Completed

Conditions: Heye´s Syndrome
Acquired Von Willebrand Disease Secondary to Severe Aortic Stenosis
Severe Aortic Stenosis

Interventions: Drug: desmopressin

First Posted Date: 2013-11-25

Last Posted Date: 2017-04-05

Lead Sponsor: Pontificia Universidad Catolica de Chile

Target Recruit Count: 13

Registration Number: NCT01994330

Locations: 🇨🇱
Hospital Clínico Universidad Católica de Chile, Santiago, Region Metropolitana, Chile

DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty

Phase 2

Terminated

Conditions: Postoperative Ecchymosis

Interventions: Drug: DDAVP

First Posted Date: 2013-11-13

Last Posted Date: 2023-08-16

Lead Sponsor: University Hospitals Cleveland Medical Center

Target Recruit Count: 14

Registration Number: NCT01982760

Locations: 🇺🇸
Lyndhurst Surgery Center, Lyndhurst, Ohio, United States

Daytime Impact Sleep Study

Phase 2

Terminated

Conditions: Nocturia

Interventions: Drug: Placebo (not active)
Drug: Desmopressin

First Posted Date: 2013-01-30

Last Posted Date: 2015-04-27

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT01779466

Locations: 🇬🇧
Surrey Clinical Research Centre, Surrey, United Kingdom

Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding

Phase 2

Completed

Conditions: Colorectal Cancer
Rectal Bleeding

Interventions: Drug: Desmopressin

First Posted Date: 2012-06-19

Last Posted Date: 2017-08-24

Lead Sponsor: Laboratorio Elea Phoenix S.A.

Target Recruit Count: 30

Registration Number: NCT01623206

Locations: 🇦🇷
Hospital de Gastroenterologia ¨B.Udaondo¨, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
🇦🇷
Instituto de Oncología "Alexander Fleming", Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Perioperative Use of Desmopressin (DDAVP) in Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Desmopressin

First Posted Date: 2012-05-25

Last Posted Date: 2015-08-28

Lead Sponsor: Laboratorio Elea Phoenix S.A.

Target Recruit Count: 21

Registration Number: NCT01606072

Locations: 🇦🇷
Hospital Interzonal General De Agudos EvaPeron, Buenos Aires, Argentina

Desmopressin for Improving Nocturnal Enuresis in Patients After Radical Cystectomy With Bladder Reconstruction

Phase 4

Conditions: Nocturnal Enuresis

Interventions: Drug: Desmopressin

First Posted Date: 2012-04-20

Last Posted Date: 2012-04-20

Lead Sponsor: Rabin Medical Center

Target Recruit Count: 50

Registration Number: NCT01582542

Locations: 🇮🇱
Institute of Urology, Rabin Medical Cetner, Petah Tiqva, Petach Tiqva, Israel

Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary

Phase 3

Completed

Conditions: Nocturia

Interventions: Drug: Placebo
Drug: Desmopressin

First Posted Date: 2012-03-13

Last Posted Date: 2017-07-11

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT01552343

Locations: 🇺🇸
Accelovance, Peoria, Illinois, United States
🇺🇸
Radiant Research, Inc., San Antonio, Texas, United States
🇺🇸
Avail Clinical Research, LLC, DeLand, Florida, United States

and more 6 locations

Platelet Function Analysis in Head Trauma: ASA/Plavix

Not Applicable

Completed

Conditions: Head Injury Trauma Blunt

Interventions: Biological: Platelets
Drug: DDAVP

First Posted Date: 2012-02-16

Last Posted Date: 2012-02-16

Lead Sponsor: Chang, Steve S., M.D.

Target Recruit Count: 97

Registration Number: NCT01534117

Locations: 🇺🇸
Santa Barbara Cottage Hospital, Santa Barbara, California, United States

Clinical Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients

Phase 3

Terminated

Conditions: Nocturia
Obstructive Sleep Apnoea

Interventions: Drug: Desmopressin
Drug: Placebo

First Posted Date: 2012-02-10

Last Posted Date: 2015-02-04

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 9

Registration Number: NCT01530451

Locations: 🇭🇰
Prince of Wales Hospital, Shatin, Hong Kong

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy